Adtalem Global Education is a buy with strong enrollment, profit growth, and demand in healthcare education. Fair value ...

List today: Pharming Group N.V. PHAR: This biopharmaceutical company has seen the Zacks Consensus Estimate for its current ...

Semrush is an undervalued gem with strong growth, profitability, and a $40B TAM. Read here for an investment analysis of SEMR ...

Tesla enters Q2 2025 at a critical juncture, balancing short-term earnings pressure with long-term growth potential driven by expansion in China and India.

Akebia Therapeutics (AKBA) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful ...

This ASX AI share is well positioned to absorb surging demand in the technology sector over the next 12 months.

Burberry's FY 2026 outlook remains cautious. Confidence hinges on sustained improvement in store performance and tight cost control. Analysts from Jefferies, HSBC, and Barclays express guarded ...

We have crunched the numbers and here is our best estimates about Amazon’s share price through the rest of the decade.

Key global macro releases due on Thursday include EUR CPI, UK unemployment, and US retail sales and jobless claims and will ...

Since its inception as a public company, Pool Corp. has spent 46% of its cash -- $2.7 billion -- on share buybacks, and 21% on dividends. In April, Pool Corp. increased its quarterly dividend by 4% to ...

Palantir is the biggest gainer in the S&P 500 so far this year. The AI-driven software company’s earnings are soaring amid ...

Microsoft has robust fundamentals and significant lucrative growth avenues. The company's dividend growth program looks about ...